WO2008064072A3 - Anti-tsg101 antibodies and their uses for treatment of viral infections - Google Patents
Anti-tsg101 antibodies and their uses for treatment of viral infections Download PDFInfo
- Publication number
- WO2008064072A3 WO2008064072A3 PCT/US2007/084808 US2007084808W WO2008064072A3 WO 2008064072 A3 WO2008064072 A3 WO 2008064072A3 US 2007084808 W US2007084808 W US 2007084808W WO 2008064072 A3 WO2008064072 A3 WO 2008064072A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- viral infections
- tsg101
- antibodies
- tsg101 antibodies
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title abstract 2
- 101000613251 Homo sapiens Tumor susceptibility gene 101 protein Proteins 0.000 abstract 2
- 102100040879 Tumor susceptibility gene 101 protein Human genes 0.000 abstract 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007323799A AU2007323799B2 (en) | 2006-11-15 | 2007-11-15 | Anti-TSG101 antibodies and their uses for treatment of viral infections |
JP2009537363A JP2010510235A (en) | 2006-11-15 | 2007-11-15 | Anti-TSG101 antibody and its use for the treatment of viral infections |
CA002669095A CA2669095A1 (en) | 2006-11-15 | 2007-11-15 | Anti-tsg101 antibodies and their uses for treatment of viral infections |
NZ576878A NZ576878A (en) | 2006-11-15 | 2007-11-15 | Anti-TSG101 antibody (ATCC deposit PTA-9611) and its use for treatment of viral infection |
MX2009005026A MX2009005026A (en) | 2006-11-15 | 2007-11-15 | Anti-tsg101 antibodies and their uses for treatment of viral infections. |
EP07871484A EP2094282A4 (en) | 2006-11-15 | 2007-11-15 | Anti-tsg101 antibodies and their uses for treatment of viral infections |
IL198598A IL198598A0 (en) | 2006-11-15 | 2009-05-06 | Anti-tsg101 antibodies and their uses for treatment of viral infections |
ZA2009/04068A ZA200904068B (en) | 2006-11-15 | 2009-06-10 | Anti-tsg101 antibodies and their uses for treatment of viral infections |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85892206P | 2006-11-15 | 2006-11-15 | |
US60/858,922 | 2006-11-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008064072A2 WO2008064072A2 (en) | 2008-05-29 |
WO2008064072A3 true WO2008064072A3 (en) | 2008-10-16 |
Family
ID=39430501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/084808 WO2008064072A2 (en) | 2006-11-15 | 2007-11-15 | Anti-tsg101 antibodies and their uses for treatment of viral infections |
Country Status (11)
Country | Link |
---|---|
US (2) | US7964708B2 (en) |
EP (2) | EP2514439A1 (en) |
JP (2) | JP2010510235A (en) |
CN (1) | CN101641106A (en) |
AU (1) | AU2007323799B2 (en) |
CA (1) | CA2669095A1 (en) |
IL (1) | IL198598A0 (en) |
MX (1) | MX2009005026A (en) |
NZ (1) | NZ576878A (en) |
WO (1) | WO2008064072A2 (en) |
ZA (1) | ZA200904068B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2091971A4 (en) * | 2006-11-13 | 2010-05-05 | Functional Genetics Inc | Therapeutic targeting of escort proteins |
WO2011091395A1 (en) * | 2010-01-25 | 2011-07-28 | Functional Genetics, Inc. | Antibodies for diagnosis and therapeutic treatment of prostate cancer |
US11918728B2 (en) | 2014-04-17 | 2024-03-05 | ImMutriX Therapeutics, Inc. | Therapeutic compositions for viral-associated disease states and methods of making and using same |
US9669151B2 (en) | 2014-04-17 | 2017-06-06 | ImMutriX Therapeutics, Inc. | Therapeutic compositions for viral-associated disease states and methods of making and using same |
CN112630449B (en) * | 2020-12-30 | 2022-10-18 | 广西壮族自治区水牛研究所 | Blood exosome marker for judging buffalo birth time and application thereof |
GB202203066D0 (en) * | 2022-03-04 | 2022-04-20 | Univ Swansea | Anti-rage antibody |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004031209A2 (en) * | 2002-10-01 | 2004-04-15 | Functional Genetics, Inc. | Anti-tsg101 antibodies and their uses for treatment of viral infections |
WO2004071462A2 (en) * | 2003-02-12 | 2004-08-26 | Johns Hopkins University | Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4741900A (en) * | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (en) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | Chimera monoclonal antibody and its preparation |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (en) | 1984-12-04 | 1986-06-21 | Teijin Ltd | Expression of hybrid antibody gene |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0307434B2 (en) * | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
AU4308689A (en) | 1988-09-02 | 1990-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
KR100272077B1 (en) * | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
AU660629B2 (en) | 1990-10-01 | 1995-07-06 | University Of Connecticut, The | Targeting viruses and cells for selective internalization by cells |
CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
CA2105300C (en) | 1991-03-01 | 2008-12-23 | Robert C. Ladner | Process for the development of binding mini-proteins |
DK1471142T3 (en) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimeric receptor libraries using phagemids |
CA2103064A1 (en) | 1991-05-14 | 1992-11-15 | George Y. Wu | Targeted delivery of genes encoding immunogenic proteins |
CA2103371C (en) | 1991-06-05 | 2003-09-16 | George Y. Wu | Targeted delivery of genes encoding secretory proteins |
DE69233254T2 (en) * | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanized Heregulin antibody |
DE4122599C2 (en) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid for screening antibodies |
JP3951062B2 (en) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | Expression of antibody fragments with cysteine present at least as a free thiol in E. coli for the production of bifunctional F (ab ') 2 antibodies |
US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
AU3434393A (en) | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
JPH07505773A (en) | 1992-04-03 | 1995-06-29 | ヤング アレキサンダー ティー | Gene therapy using targeted viral vectors |
AU689758B2 (en) | 1992-10-09 | 1998-04-09 | Advanced Tissue Sciences, Inc. | Liver reserve cells |
CA2115811A1 (en) * | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
WO1997018333A1 (en) * | 1995-11-16 | 1997-05-22 | The Board Of Trustees Of The Leland Stanford Junior University | Disruption of expression of multiple alleles of mammalian genes |
US5914112A (en) * | 1996-01-23 | 1999-06-22 | Genentech, Inc. | Anti-CD18 antibodies in stroke |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
US20020177207A1 (en) * | 2001-03-14 | 2002-11-28 | Myriad Genetics, Incorporated | Tsg101-interacting proteins and use thereof |
ES2328796T3 (en) | 2001-03-14 | 2009-11-18 | Myriad Genetics, Inc. | TSG101-GAG INTERACTION AND USE OF THE SAME. |
US7335468B2 (en) * | 2001-03-14 | 2008-02-26 | Myriad Genetics, Inc. | TSG101-GAG interaction and use thereof |
WO2002094314A1 (en) * | 2001-05-21 | 2002-11-28 | The Research Foundation Of The State University Of New York | Tsg101 as inhibitor of hiv production |
-
2007
- 2007-11-15 AU AU2007323799A patent/AU2007323799B2/en not_active Ceased
- 2007-11-15 CN CN200780049912A patent/CN101641106A/en active Pending
- 2007-11-15 NZ NZ576878A patent/NZ576878A/en not_active IP Right Cessation
- 2007-11-15 MX MX2009005026A patent/MX2009005026A/en active IP Right Grant
- 2007-11-15 EP EP12176750A patent/EP2514439A1/en not_active Withdrawn
- 2007-11-15 EP EP07871484A patent/EP2094282A4/en not_active Withdrawn
- 2007-11-15 WO PCT/US2007/084808 patent/WO2008064072A2/en active Application Filing
- 2007-11-15 US US11/940,714 patent/US7964708B2/en not_active Expired - Fee Related
- 2007-11-15 CA CA002669095A patent/CA2669095A1/en not_active Abandoned
- 2007-11-15 JP JP2009537363A patent/JP2010510235A/en active Pending
-
2008
- 2008-04-18 US US12/105,462 patent/US8796423B2/en not_active Expired - Fee Related
-
2009
- 2009-05-06 IL IL198598A patent/IL198598A0/en unknown
- 2009-06-10 ZA ZA2009/04068A patent/ZA200904068B/en unknown
-
2013
- 2013-07-04 JP JP2013141105A patent/JP2013227331A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004031209A2 (en) * | 2002-10-01 | 2004-04-15 | Functional Genetics, Inc. | Anti-tsg101 antibodies and their uses for treatment of viral infections |
WO2004071462A2 (en) * | 2003-02-12 | 2004-08-26 | Johns Hopkins University | Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction |
Non-Patent Citations (1)
Title |
---|
ZHONG. Q.: "Identification of cellular TGS101 Protein in MUltiple Human Breast Cancer Cell Lines.", CANCER RESEARCH, vol. 57, October 1997 (1997-10-01), pages 4225 - 4228, XP008109846 * |
Also Published As
Publication number | Publication date |
---|---|
ZA200904068B (en) | 2012-09-29 |
JP2010510235A (en) | 2010-04-02 |
AU2007323799A1 (en) | 2008-05-29 |
CA2669095A1 (en) | 2008-05-29 |
AU2007323799B2 (en) | 2013-07-18 |
CN101641106A (en) | 2010-02-03 |
US20080187528A1 (en) | 2008-08-07 |
US8796423B2 (en) | 2014-08-05 |
EP2514439A1 (en) | 2012-10-24 |
WO2008064072A2 (en) | 2008-05-29 |
EP2094282A2 (en) | 2009-09-02 |
US20090186041A1 (en) | 2009-07-23 |
EP2094282A4 (en) | 2010-05-05 |
NZ576878A (en) | 2011-10-28 |
MX2009005026A (en) | 2009-07-31 |
IL198598A0 (en) | 2010-02-17 |
JP2013227331A (en) | 2013-11-07 |
US7964708B2 (en) | 2011-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008115281A3 (en) | Compounds for treating viral infections | |
WO2011071574A3 (en) | Monoclonal antibodies against glycoprotein of ebola sudan boniface virus | |
WO2008127364A3 (en) | Antiviral compounds and use thereof | |
EP3266464A3 (en) | Yeast-based therapeutic for chronic hepatitis b infection | |
WO2004018649A3 (en) | Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein | |
CY1114356T1 (en) | SUSPENSION VIRUS INHIBITIONS C | |
WO2010047830A3 (en) | Agents for hcv treatment | |
EA201200277A1 (en) | ANTIBODIES AGAINST THE RESPIRATORY SYNCTIAL VIRUS (PCB) AND METHODS OF THEIR APPLICATION | |
WO2012006596A3 (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
WO2006110831A3 (en) | Method of inducing neutralizing antibodies to human immunodeficiency virus | |
WO2007095318A3 (en) | Influenza antigens, vaccine compositions, and related methods | |
WO2007041487A3 (en) | Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family | |
WO2009067191A3 (en) | Methods and compositions for the treatment of hepatitis c virus (hcv) infection | |
WO2009081285A3 (en) | Hepatitis c virus antibodies | |
WO2007084435A3 (en) | Methods for treating hepatitis c | |
WO2010056898A3 (en) | Rapid expression cloning of human monoclonal antibodies from memory b cells | |
EA201000948A1 (en) | VIRAL POLYMERASE INHIBITORS | |
WO2008064072A3 (en) | Anti-tsg101 antibodies and their uses for treatment of viral infections | |
WO2008133734A3 (en) | Method and compositions for treating hiv infections | |
WO2008118849A3 (en) | Hiv-1 protease inhibitors | |
EA201300132A1 (en) | PHARMACEUTICAL COMPOSITION AND METHODS OF TREATMENT AND PREVENTION OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV | |
WO2006085979A3 (en) | Soluble forms of hendra and nipah virus g glycoprotein | |
WO2010064822A2 (en) | Effective control of viral plant disease with strains of pseudomonas oleovorans | |
WO2013033319A3 (en) | A cluster of neutralizing antibodies to hepatitis c virus | |
WO2006019841A3 (en) | Treatment of viral infections with egr 1 activators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780049912.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07871484 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 198598 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007323799 Country of ref document: AU Ref document number: 2669095 Country of ref document: CA Ref document number: 576878 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/005026 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2009537363 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007323799 Country of ref document: AU Date of ref document: 20071115 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3829/DELNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007871484 Country of ref document: EP |